First-in-class GPCR inhibitor targeting BxR eye drops for retinal diseases
Small molecule IND Global Ophthalmology disease
Boston
|
San Jose
|
Newark
|
Frankfurt
London
|
Basel
|
Beijing
|
Shanghai
Hangzhou
|
Suzhou
Stay Connected and Get Updates
Subscribe newsletter